Pemvidutide

Phase 2Peptide

Pemvidutide is a peptide that works as a Glp-1/glucagon Dual Agonist.[2] It is being investigated across 4 indications, with its most advanced program in Phase 2.[1]

Pemvidutide is one of 111 peptide programs targeting Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

110

Competitors

Pipeline

Status by Indication[3][1]

Indication

HepatitisActive, not recruiting

Liver DiseaseActive, not recruiting

ObesityActive, not recruiting

NASH/MASHActive, not recruiting

HepatitisPhase 2

Active, not recruiting

Liver DiseasePhase 2

Active, not recruiting

ObesityPhase 2

Active, not recruiting

NASH/MASHPhase 2

Active, not recruiting

Competition

Competitive Landscape

392 competitors in Obesity

#DrugCompanyPhaseTrials

Pemvidutide

Altimmune

Phase 2

4 2

Avapro

Sanofi

Preclinical

1 3

Amidate

Pfizer

Preclinical

—4

Calciferol

Alnylam Pharmaceuticals

Adenocard

Activella

Colcrys

Alnylam Pharmaceuticals

Preclinical

—8

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 9

Cetrotide

EMD Serono

Preclinical

2 10

Spiriva

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Liver Disease

NCT07009860

Clinical

Trials by Indication[1]

Hepatitis1 trial

IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

Completed· Altimmune logo

Altimmune·Phase 2·NCT05989711·212 enrolled

Overweight1 trial

RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

Active, not recruiting· Altimmune logo

Altimmune·Phase 2·NCT06987513·100 enrolled

Liver Disease1 trial

RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

Recruiting· Altimmune logo

Altimmune·Phase 2·NCT07009860·100 enrolled

Unspecified1 trial

Pemvidutide (ALT-801) DDI Study in Healthy Volunteers

Completed· Altimmune logo

Altimmune·Phase 1·NCT04972396·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Pemvidutide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pemvidutide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pemvidutide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Altimmune company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Glp-1/glucagon Dual Agonist[2]
Modality: Peptide[2]
Highest Phase: Phase 2[1]
Company: Altimmune

Pemvidutide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hepatitis1 trial

Overweight1 trial

Liver Disease1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News